Shield Therapeutics is well positioned to become a fast growing, independent, international specialty pharmaceutical company.

Why invest in Shield Therapeutics?

Shield has transformed from a development-focused, privately owned company into a PLC with increasingly commercially focused, customer-facing organisation set up to sell our innovative and value-added specialty pharmaceuticals that solve patients’ unmet medical needs.


Annual Revenue

Targeted for Ferracru


Annual Revenue

Targeted for PT20


Amount Raised

Since 2010

London, UK

One Euston Square
40 Melton Street
London, NW1 2FD

t+44 (0) 207 186 8500

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

Wollerau, Switzerland

Shield Therapeutics
c/o Shield Holdings AG
Sihleggstrasse 23, 8832 Wollerau

t+41 (0) 435 080 781

Munich, Germany

Shield Therapeutics (DE)
Leopoldstr. 23
80802 München, Germany